CN119789856A - 施用肌球蛋白抑制剂的方法 - Google Patents

施用肌球蛋白抑制剂的方法 Download PDF

Info

Publication number
CN119789856A
CN119789856A CN202380047093.0A CN202380047093A CN119789856A CN 119789856 A CN119789856 A CN 119789856A CN 202380047093 A CN202380047093 A CN 202380047093A CN 119789856 A CN119789856 A CN 119789856A
Authority
CN
China
Prior art keywords
patient
dose
treatment period
mevalonate
lvef
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380047093.0A
Other languages
English (en)
Chinese (zh)
Inventor
V·V·佩雷拉
S·梅拉利
A·塞纳特
M·张
D·塞托
J·劳克曼
M-L·帕皮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myokardia Inc
Original Assignee
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myokardia Inc filed Critical Myokardia Inc
Priority to CN202510520246.XA priority Critical patent/CN120549937A/zh
Publication of CN119789856A publication Critical patent/CN119789856A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/06—Measuring blood flow
    • A61B8/065—Measuring blood flow to determine blood output from the heart
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H15/00—ICT specially adapted for medical reports, e.g. generation or transmission thereof
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202380047093.0A 2022-04-26 2023-04-25 施用肌球蛋白抑制剂的方法 Pending CN119789856A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510520246.XA CN120549937A (zh) 2022-04-26 2023-04-25 施用肌球蛋白抑制剂的方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263335209P 2022-04-26 2022-04-26
US202263335028P 2022-04-26 2022-04-26
US63/335,209 2022-04-26
US63/335,028 2022-04-26
US202263336254P 2022-04-28 2022-04-28
US63/336,254 2022-04-28
PCT/US2023/019710 WO2023211872A1 (en) 2022-04-26 2023-04-25 Methods of administering myosin inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510520246.XA Division CN120549937A (zh) 2022-04-26 2023-04-25 施用肌球蛋白抑制剂的方法

Publications (1)

Publication Number Publication Date
CN119789856A true CN119789856A (zh) 2025-04-08

Family

ID=86558746

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202380047093.0A Pending CN119789856A (zh) 2022-04-26 2023-04-25 施用肌球蛋白抑制剂的方法
CN202510520246.XA Pending CN120549937A (zh) 2022-04-26 2023-04-25 施用肌球蛋白抑制剂的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510520246.XA Pending CN120549937A (zh) 2022-04-26 2023-04-25 施用肌球蛋白抑制剂的方法

Country Status (12)

Country Link
US (4) US20230338378A1 (enExample)
EP (1) EP4514355A1 (enExample)
JP (1) JP2025515491A (enExample)
KR (1) KR20250016125A (enExample)
CN (2) CN119789856A (enExample)
AU (1) AU2023260472A1 (enExample)
CA (1) CA3249509A1 (enExample)
CL (1) CL2024003237A1 (enExample)
IL (1) IL316204A (enExample)
MX (1) MX2024013068A (enExample)
TW (1) TW202400570A (enExample)
WO (1) WO2023211872A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019144041A1 (en) 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP7610985B2 (ja) 2018-06-26 2025-01-09 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
PT4370116T (pt) 2021-07-16 2025-03-14 Cytokinetics Inc Regimes de administração de aficamten para o tratamento da cardiomiopatia hipertrófica obstrutiva
WO2024182469A1 (en) * 2023-02-28 2024-09-06 MyoKardia, Inc. Myosin inhibitors for use in the treatment of hypertrophic cardiomyopathy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9585885B2 (en) * 2012-12-10 2017-03-07 Kissei Pharmaceutical Co., Ltd. Substituted pyrido[2,3-g]quinazolines as dopamine D2 receptor agonists
SMT202000071T1 (it) 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache
WO2019144041A1 (en) 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP7610985B2 (ja) 2018-06-26 2025-01-09 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
EP4054588A4 (en) * 2019-11-10 2023-12-13 MyoKardia, Inc. Methods of treatment with myosin modulator
MX2023002024A (es) * 2020-08-28 2023-05-10 Myokardia Inc Métodos de tratamiento con modulador de miosina.

Also Published As

Publication number Publication date
CL2024003237A1 (es) 2025-02-07
JP2025515491A (ja) 2025-05-15
EP4514355A1 (en) 2025-03-05
TW202400570A (zh) 2024-01-01
US20250360132A1 (en) 2025-11-27
US20240115568A1 (en) 2024-04-11
US20250288586A1 (en) 2025-09-18
US20230338378A1 (en) 2023-10-26
CA3249509A1 (en) 2023-11-02
AU2023260472A1 (en) 2024-10-24
IL316204A (en) 2024-12-01
MX2024013068A (es) 2025-02-10
WO2023211872A1 (en) 2023-11-02
CN120549937A (zh) 2025-08-29
KR20250016125A (ko) 2025-02-03

Similar Documents

Publication Publication Date Title
CN119789856A (zh) 施用肌球蛋白抑制剂的方法
Writing Committee et al. 2022 ACC expert consensus decision pathway for integrating atherosclerotic cardiovascular disease and multimorbidity treatment: a framework for pragmatic, patient-centered care: a report of the American College of Cardiology Solution Set Oversight Committee
Goupil et al. Hypertension Canada guideline for the diagnosis and treatment of hypertension in adults in primary care
US20230360760A1 (en) Methods of regulating access to qsymia to mitigate potential drug-associated risks
Te Karu et al. Maori experiences and perceptions of gout and its treatment: a kaupapa Maori qualitative study
Hong et al. Grey–white matter ratio measured using early unenhanced brain computed tomography shows no correlation with neurological outcomes in patients undergoing targeted temperature management after cardiac arrest
Kane et al. The challenge of compliance and persistence: focus on ulcerative colitis
Arora et al. Project ECHO: an effective means of increasing palliative care capacity
Jones et al. Characterization of glaucoma medication adherence in Kaiser Permanente Southern California
Wartna et al. Symptomatic treatment of pollen‐related allergic rhinoconjunctivitis in children: randomized controlled trial
Brooks III et al. Safety and tolerability associated with second-generation antipsychotic polytherapy in bipolar disorder: findings from the Systematic Treatment Enhancement Program for Bipolar Disorder
JP2018508476A (ja) 個別化薬物療法のための方法
Deplanque et al. Drug repurposing: from the discovery of a useful pharmacological effect to making the treatment available to the patient
Akao et al. Comprehension of nonvalvular atrial fibrillation and anticoagulant adherence in elderly patients in a subcohort study of the all Nippon atrial fibrillation in the elderly registry
Schulz et al. Impact of a medication management system on nursing home admission rate in a community-dwelling nursing home–eligible Medicaid population
Van Der Valk et al. Predicting intraocular pressure change before initiating therapy: timolol versus latanoprost
Klein et al. Models for drug individualization: patient to population level
Larmer et al. Impact of pharmacist collaborative practice agreement on pharmacogenomic implementation for patients referred from geriatric medicine
García García et al. Frailty and Medication Appropriateness in Rural Adults: Proposing Interventions through Pharmacist–Physician Collaborative Efforts
Overholser et al. Patients with Cancer and Survivors
TIMing randomised controlled trial
DR Jr et al. 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes: Executive Summary
Weatherald et al. Real-world persistence of selexipag for pulmonary arterial hypertension in Canada
Zapatero-Gaviria et al. Management of hospital readmissions in internal medicine
Mak et al. Incorporating Geriatric Assessment Tools and the American Geriatric Society Patient Care Domains into the Pharmacists’ Patient Care Process

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination